Esophageal adenocarcinoma

This trial is testing whether a combination of the immunotherapy drug durvalumab, chemotherapy, and radiation can completely eliminate early-stage esophageal cancer, potentially making surgery unnecessary. The study enrolls adults with early-stage (cT1 or cT2N0) esophageal adenoc…

This early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…

This phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…

This phase 2 trial tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. Researchers will measure levels of a protein linked to Barrett's in tissue samples from 21 participants over 12 mont…

This study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…

This study tests adding the immunotherapy drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination to see if it is safe and effective. The goal is to improve cancer control withou…

This early-phase trial tests whether adding a cancer-killing virus called OBP-301 to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. Sixtee…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…

This study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…

This study compares two radiation techniques for people with stage I to IVA esophageal cancer: proton beam therapy (which uses protons) and intensity modulated photon radiotherapy (which uses X-rays). The goal is to see which one works better at helping people live longer and cau…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…

This study is testing whether adding two immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can help control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo …

This phase 2 trial is testing whether a combination of trifluridine/tipiracil (Lonsurf) plus oxaliplatin, with or without the immunotherapy nivolumab, can help people with advanced HER2-negative stomach, esophageal, or gastroesophageal junction cancer. The study compares these co…

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will recei…

This early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…

This early-phase trial investigates whether itraconazole, a common antifungal medication, can reduce the risk of cancer in people with high-risk Barrett's esophagus who have already undergone endoscopic ablation. Barrett's esophagus often returns after treatment, increasing the c…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …

This study tests whether adding a pill called vactosertib to standard chemoradiotherapy can improve outcomes for people with esophageal cancer. Participants take vactosertib for two weeks before and after standard treatment, then undergo surgery. The goal is to see if the drug he…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study is for people with HER2-positive esophageal or gastroesophageal junction cancer who have already completed chemoradiation and surgery. The goal is to see if adding a year of treatment with trastuzumab deruxtecan (Enhertu) plus nivolumab is safe and helps prevent the ca…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with a certain type of esophageal cancer. The trial involves 42 adults whose cancer has not spread far but is locally advanced. The main goal is to see if t…

This study looks at whether ablation therapy (using heat or light to destroy abnormal cells) can control Barrett's esophagus, a condition that can lead to esophageal cancer. About 600 adults with high-grade dysplasia or early cancer will be treated and followed to see if the abno…

This phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This phase 2 trial is testing a two-step treatment for esophageal cancer. First, patients receive a chemotherapy combination called FLOT, followed by chemoradiation (chemo plus radiation). After that, they have surgery to remove the tumor. The goal is to see if this approach lead…

This early-phase trial tests a new approach for people with locally advanced esophageal cancer. Before surgery, patients receive proton beam radiotherapy along with two chemotherapy drugs (carboplatin and paclitaxel). The main goal is to find the safest dose and see how well pati…

This study is testing a simple, less invasive way to detect Barrett's esophagus and esophageal cancer using a sponge on a string. Participants swallow the sponge, which collects cells from the esophagus. Researchers will analyze these cells to develop a lab test that can spot ear…

This study tests a device called Endosign, which is a sponge on a string that patients swallow to collect cells from the esophagus. The goal is to see if this simple, non-sedation method can provide good enough samples to replace regular endoscopies for monitoring Barrett's esoph…

This study looks at whether a simple, swallowable device can help screen for esophageal cancer in rural Oregon, where getting a traditional endoscopy is hard. About 110 adults with chronic heartburn and other risk factors will try the device at their local clinic. Researchers wan…

Researchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study is testing whether an artificial intelligence (AI) model can help doctors better detect, diagnose, and treat esophageal cancer. Researchers will feed de-identified data from 12,000 patients receiving routine care into the AI and compare its recommendations to standard …

This study aims to find early DNA changes in blood and esophageal tissue that could signal a higher risk of developing esophageal cancer. Researchers are studying 600 people with gastroesophageal reflux, Barrett's esophagus, or esophageal cancer who are already scheduled for an u…

This study explores whether a dye called indocyanine green (ICG) and a special camera can help surgeons find the first lymph nodes that esophageal cancer may spread to. If this 'sentinel lymph node' mapping works, future surgeries might remove only those key nodes instead of all …

This study collects blood and tissue samples from 1,000 adults with Barrett's esophagus or esophageal cancer during their routine endoscopy. The goal is to build a biorepository that links clinical data with specimens, enabling future research into these conditions. Participants …

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…